

Curriculum Vitae

Rüdiger HEHLMANN, o. Prof. Dr. med. Dr. h. c.



Personal data ELN Foundation
Im Langgewann 45, 69469 Weinheim
hehlmann.eln@gmail.com
Medizinische Fakultät Mannheim, Universität Heidelberg

Education

1961 – 1966 Study of Medicine at Marburg, Freiburg, Edinburgh, Munich
Graduation: December 1966
1967 - 1969 MD-PhD Scholar Max-Planck-Institut für Biochemie, Munich
(Peter-Hans Hofschneider). Graduation July 1969
Stevenson Exchange Scholar (Edinburgh) 1964-1965
Studienstiftung des Deutschen Volkes 1963-1969

Academic Career

1969- 1970 Research assistant, Max-Planck-Institut für Biochemie, Munich
1970 Research fellow, Dept of Biology, University of Rochester, N. Y. (Stan Hattman)
1970 - 1973 Research Associate (Sol Spiegelman) and Lecturer in Human Genetics and
Development at Institute of Cancer Research, Columbia University, New York
Research on Retroviruses, Search for a Human Leukemia Virus
1973 - 1974 Intern in Medicine, Columbia-Presbyterian Medical Center
Licence to practice Medicine and Surgery in the State of New York, 16.9.1974
7-11/1974 Clinical Fellow at Memorial Sloan Kettering Cancer Center (Bayard Clarkson)
12/1974 -1981 Physician, Medizinische Poliklinik, Munich University (Nepomuk Zöllner)
1977 Boards of Internal Medicine
1979 Habilitation (Dr. med. habil.)
1981 - 1988 Professor of Medicine, Munich University
Shift from retrovirus research towards clinical trials on CML
Foundation of the German CML Study Group
1984 Boards of Hematology and Medical Oncology
1988 - 2007 Professor of Medicine, Heidelberg University and
Chief, III. Medizinische Universitätsklinik Mannheim
2007 - 2017 Research Professorship, Med. Fakultät Mannheim
1999 - 2001 Dean, Med. Fakultät Mannheim
1999 Foundation of the Kompetenznetz Akute und chronische Leukämien
2002 Foundation of the European LeukemiaNet (ELN)
1995 - 2009 President and Secretary General, International Association for Comparative Research
on Leukemia and Related Diseases (IACRLRD)
2000 - 2001 President, German Society for Hematology and Oncology
2009 President, 14. EHA-Congress, Berlin
2017- current Coordination, European LeukemiaNet, Clinical CML Research

Research

- 1970ff. Retroviral work. Search for a human leukemia virus resulting in the detection of retrovirus-related RNA and reverse transcriptase in human cells and
- 1986 Isolation of a complete human endogenous retrovirus related to a primate leukemia virus.
- 1984 First HIV-seroepidemiology in Germany
- 1997-2022 Laboratory and clinical studies on the role of chromosomal aberrations (aneuploidy) in leukemogenesis and carcinogenesis.
- Study of the role of aneuploidy in carcinogenesis in a hamster model (in cooperation with Peter Duesberg, guest professor at the Mannheim Faculty) resulting in the chromosomal theory of carcinogenesis.
- Since 1982 Shift towards clinical studies on leukemia (CML). Founder and chair of the German CML study group. Five randomized treatment optimization studies on CML (1983 – 2017). Profound improvement of prognosis and survival in CML.
- Since 1992 European cooperation on clinical CML-research (European Investigators on CML, EI-CML).
- Since 1997 Founder and chair of the German Competence Network on acute and chronic Leukemias (CNL) in cooperation with German leukemia study groups. Improvement and acceleration of leukemia research resulting in greater international visibility.
- Since 2002 Founder and chair of the European LeukemiaNet (ELN) based on CNL and EI-CML. The ELN has established common definitions and standards for cooperative leukemia research across Europe and internationally (ELN-recommendations). From its inception, ELN was recognized by researchers from Eastern Europe as an ideal platform to join cooperation with colleagues from the west. ELN recommendations have become international standards for diagnosis and therapy.
- 2007-2015 European Treatment and Outcome Study (EUTOS) for CML to determine the epidemiology of CML in Europe, define standards for molecular monitoring and spread excellence by regular meetings.
- At present Clinical CML research. Consolidation of European and international cooperation within ELN. Outreach to new countries.

Research support:

Mostly public and foundations (EU, BMBF, Krebshilfe, Carreras, DFG), one third industry.

Academic activities

- 1981 - 1988 Vice chairman, Society for Morphology and Physiology, Munich
- 1986 - 1990 Vice chairman, Süddeutsche Hämoblastosegruppe (SHG)
- 1987 Advisor, AIDS-Hearing at Bayerischer Landtag
- 1987 - 1988 Advisor, Enquete Commission on AIDS of the German Bundestag
- 1989 - 1991 Delegate for AIDS of the Federal Ministry for Research and Technology to the European Commission in Brussels
- 1990 - 2008 Steering Committee, Cancer Center Heidelberg/Mannheim
- 2005 - 2007 Steering Committee, Interdisciplinary Tumor Center Mannheim (ITM)
- 1996 Advisory Committee Cost evaluation of clinical University Medicine, German Federal Government
- 1993 - 1998 Review Committee Infectious Diseases, Federal Ministry for Research and Technology
- 1995 - 1999 Review Committee Public Health, Federal Ministry for Research and Technology
- 1995- current Scientific Advisory Board, José Carreras Leukämie Stiftung
- 1996 - 2000 CML-Guidelines Committee, American Society of Hematology (ASH)
- 1996 - 2004 Advisory Board, German Society for Hematology and Oncology (DGHO)
- 1997 - 2000 Delegate, German Society for Hematology and Oncology to the Working Party of Scientific Medical Societies (AWMF)
- 1999 - 2001 Dean, Medical Faculty Mannheim of Heidelberg University
- 2001 - 2017 Steering Committee, German AML Intergroup
- 1999 Foundation of the Kompetenznetz Akute und chronische Leukämien
- 2002 Foundation of the European LeukemiaNet (ELN)
- 1995 - 2009 President and Secretary General, International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD)
- 2000 - 2001 President, German Society for Hematology and Oncology
- 2009 President, 14. EHA-Congress, Berlin
- 2017- current Coordination, European LeukemiaNet; Clinical CML Research

Organization of International Conferences (88)

- 1992 - 2017 25 Annual International Workshops on CML in Weinheim, Mannheim and Heidelberg
- 1997, 2005 XIX., and XXII. Symposium of the IACRLRD in Mannheim and Heidelberg
- 2001 Annual Congress of the German and Austrian Societies of Hematology and Oncology (DGHO/ÖGHO) in Mannheim
- 2003 11. Annual Meeting of the European Investigators on CML (EI-CML) in Berlin
- 1999 - 2003 4 Annual Symposia of the Kompetenznetz "Akute und chronische Leukämien" in Heidelberg
- 2004 - 2024 20 Annual ELN-Symposia in Heidelberg, Mannheim and Venice
- 2002 - 2023 20 Annual ELN Breakfast Meetings at ASH in Philadelphia, Atlanta (4x), San Diego (6x), Orlando (4x), San Francisco (2x) and New Orleans (3x)

2006 - 2014 9 ELN-Frontiers Meetings in Venice, Budapest, Cannes, Barcelona, Vienna, Prague, Istanbul, Berlin (2x) (with M. Baccarani)

2009 - 2014 6 ELN - Educational Meetings for young European hematologists in Naples, Italy (with F. Pane)

CML Study Group Meetings

1982 - 2017 70 CML Study Group Meetings, twice annually, in Günzburg (Reisensburg), Weinheim (Wachenburg), Heidelberg and Mannheim

Honors

1984 Curt Bohneward-Prize for Scientific Cooperation in Cancer Research

1990 GSF-Prize for Interdisciplinary Cooperation

1999 Paul Martini-Prize for Improvement of Prognosis in CML

2000 Ehrenschild for Community Service, Kulturverein Waldhof, Mannheim

2004 R.T. Silver-Visiting Professor, Weill-Cornell Medicine, New York, USA

2005 Honorary Member of the Polish Society for Hematology and Transfusion Medicine

2007 Grand Rounds, DKFZ Heidelberg

2008 Honorary Member of the German Society for Hematology and Oncology

2009 Visiting Professor Emory University, Atlanta, USA

2009 Johann Georg Zimmermann-Medal for the Treatment of Leukemia

2011 Jubilee lecture 50 years IACRLRD, Tokyo, Japan

2011 Honorary doctor of the University Uppsala, Sweden

2012 Wilhelm Warner-Prize for the Fight against Cancer

2014 John Goldman-Prize with Lecture, Philadelphia, USA

2019 Award of Excellence in Translational Research, New York, USA

2021 EHA-Education and Mentoring Award

2024 R. T. Silver Visiting Professorship Weill-Cornell Medicine, New York, USA

2006 - 2019: 7 Name Lectures in Czechia, Germany, Italy, Russia, USA and South Korea

Publications

468 peer-reviewed ; 125 book chapters, translations, articles, reviews

Editor: AIDS-Forschung (AIFO). Schulz 1986-1996
Chronic Myeloid Leukemia. Springer 2016,
2nd Edition 2021
Chinese translation 2023

Section Editor: Leukemia, for CML 1996-2007

Guest Editor: Best Practice & Research in Clinical Haematology 2009
Annals of Hematology 2015

Article on R. Hehlmann: Cancer. 2017, Sept 1; 3209-3210

Selected Publications (2014 - 2024)

Guilhot, F. & **Hehlmann, R.** (2024). Long-term outcome of tyrosine kinase inhibitors in chronic myeloid leukemia. *Blood*, 2024 Nov 1: blood.2024026311. doi: 10.1182/blood.2024026311. Online ahead of print.

Hehlmann, R., & Lauseker, M. (2024). How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies. *Leukemia*, 38(2), 465-466.

Lauseker, M., **Hehlmann, R.**, Hochhaus, A., & Saußebe, S. (2023). Survival with chronic myeloid leukaemia after failing milestones. *Leukemia*, 37(11), 2231-2236.

Niederwieser, D., Lang, T., Krahl, R., Heinicke, T., Maschmeyer, G., Al-Ali, H. K., ... & **Hehlmann, R.**, Berdel E.-B., Pfirrmann, M., Krug, U., Hoffmann, V. S. (2023). Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. *Annals of Hematology*, 102(3), 547-561.

Marchetti, M., Vannucchi, A. M., Griesshammer, M., Harrison, C., Koschmieder, S., Gisslinger, H., ... & **Hehlmann, R.**, Kiladjian, J.-J., Barbui, T. (2022). Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. *The Lancet Haematology*, 9(4), e301-e311.

Hehlmann, R., Lauseker, M., Voskanyan, A., Fabarius, A., Haferlach, C., Hochhaus, A., & Saußebe, S. (2022). Impact of emerging ACA on survival in chronic myeloid leukemia (CML). *Leukemia*, 36(10), 2544-2547.

Saglio, G., Rosti, G., **Hehlmann, R.**, Hochhaus, A., & Gale, R. P. (2022). Prof. Michele Baccarani. August 16, 1942 to December 20, 2021: a gifted life in haematology. *Leukemia*, 36(4), 1199-1200.

Gambacorti-Passerini, C., Chen, C., Davis, C., Sen, G. P., Guyan, C., **Hehlmann, R.**, ... & Goldberg, S. L. (2021). Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. *European journal of haematology*, 106(1), 82-89.

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., ... & **Hehlmann, R.** (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia*, 34(4), 966-984.

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., **Hehlmann, R.**, .. & Hoffmann, V. S. (2020). The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. *Leukemia*, 34(8), 2138-2149.

Hehlmann, R. (2020). Chronic myeloid leukemia in 2020. *Hemasphere*, 4(5).

Hehlmann, R., Voskanyan, A., Lauseker, M., Pfirrmann, M., Kalmanti, L., Rinaldetti, S., ... & Baccarani, M. (2020). High-risk additional chromosomal abnormalities at low blast counts herald death by CML. *Leukemia*, 34(8), 2074-2086.

Hehlmann, R. (2020). The new ELN recommendations for treating CML. *Journal of Clinical Medicine*, 9(11), 3671.

Radivoyevitch, T., Weaver, D., Hobbs, B., Maciejewski, J. P., **Hehlmann, R.**, Jiang, Q., ... & Gale, R. P. (2020). Do persons with chronic myeloid leukaemia have normal or near normal survival? *Leukemia*, 34(2), 333-335.

Hehlmann, R., Cortes, J. E., Zyczynski, T., Gambacorti-Passerini, C., Goldberg, S. L., Mauro, M. J., ... & Paquette, R. L. (2019). Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients

with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. *American journal of hematology*, 94(1), 46-54.

T Lange, C Niederwieser, A Gil, R Krahl, U von Grünhagen, H-K Al-Ali, K Jentsch-Ullrich, C Spohn, V Lakner, M Assmann, C Junghanss, M Cross, **R Hehlmann**, M Deininger, M Pfirrmann & D Niederwieser (2020) No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group, *Leukemia & Lymphoma*, 61:12, 2821-2830

Mughal, T. I., Gotlib, J., Mesa, R., Koschmieder, S., Khoury, H. J., Cortes, J. E., Barbui, T., **Hehlmann, R.**, ... & Abdel-Wahab, O. (2018). Recent advances in the genomics and therapy of BCR/ABL1-positive and-negative chronic myeloproliferative neoplasms. *Leukemia research*, 67, 67-74.

C Schütz, S Inselmann, S Saussele, C T Dietz, M C Müller, E Eigendorff, C A Brendel, S K Metzelder, T H Brümmendorf, C Waller, J Dengler, M E Goebeler, R Herbst, G Freunek, S Hanzel, T Illmer, Y Wang, T Lange, F Finkernagel, **R Hehlmann**, M Huber, A Neubauer, A Hochhaus, J Guilhot, F X Mahon, M Pfirrmann, A Burchert (2018). Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. *Leukemia*, 32(4), 1054.

Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, **Hehlmann R**, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*. 2018 May;32(5):1057-1069.

Saussele S, **Hehlmann R**, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. *Leukemia*. 2018 May;32(5):1222-1228.

Hehlmann R. Advancing a field by building consortia: The example of the European LeukemiaNet. *Cancer*. 2018 Mar 15;124(6):1100-1104.

Hehlmann R, Lauseker M, Saußebe S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Etinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. *Leukemia*. 2017 Nov;31(11):2398-2406.

Khoury HJ, Williams LA, Atallah E, **Hehlmann R**. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. *Am Soc Clin Oncol Educ Book*. 2017; 37:468-479.

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, **Hehlmann R**. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second-generation tyrosine kinase inhibitors for chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2017 Jul;143(7):1311-1318.

Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, **Hehlmann R**, Pfirrmann M; German CML Study Group. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. *Cancer*. 2017 Jul 1;123(13):2467-2471.

Hehlmann R. Innovation in hematology. Perspectives : CML 2016. *Haematologica* (2016);101(6):657-9.

Stegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, **Hehlmann R**, Clark RE. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. *Leukemia*. 2016;30, 1648-71

Kossak-Roth U, Sauße S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbüget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, **Hehlmann R**. [Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2016 Apr;59(4):444-53.

Büchner T, Krug UO, Gale RP, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, **Hehlmann R**, Wörmann BJ, Berdel WE, Hiddemann W. Age, not therapy-intensity, determines outcomes of adults with acute myeloid leukaemia. *Leukemia*. 2016 Aug;30(8):1781-4.

Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, **Hehlmann R**, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. *J Natl Cancer Inst*. 2016 Mar 4;108(7).

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, **Hehlmann R**, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. *Leukemia*. 2016 Jun;30(6):1230-6.

Gratwohl A, Pffirmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Sauße S, Hochhaus A, **Hehlmann R**. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia-A randomized comparison of stem cell transplantation with drug treatment. *Leukemia* 2016; 30:562-569

Pffirmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkuppe G, Hoffmann VS, Castagnetti F, Hasford J, **Hehlmann R**, Simonsson B. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia *Leukemia*. 2016 Jan;30(1):48-56.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pffirmann M, Hasford J, Krause S, Hochhaus A, Sauße S, **Hehlmann R**; SAKK and the German CML Study Group. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. *Ann Hematol*. 2015 Dec;94(12):2015-24

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Giskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, **Hehlmann R**. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. *Leukemia*. 2015 Jun;29(6):1336-43

Hehlmann R. CML--Where do we stand in 2015? *Ann Hematol.* 2015 Apr;94 Suppl 2:S103-5

Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, **Hehlmann R.** Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. *Leukemia.* 2015 May;29(5):1123-32

Talpaz M, Mercer J, **Hehlmann R.** The interferon-alpha revival in CML. *Ann Hematol.* 2015 Apr;94 Suppl 2:S195-207

Saußele S, Krauß MP, **Hehlmann R,** Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Oppliger Leibundgut E, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML-Study IV. *Blood.* 2015 Apr 27. pii: blood-2015-01-617993

Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Grieshammer M, Harrison C, **Hehlmann R,** Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardananani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical endpoints for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). *Leukemia.* 2014 Aug 25

Hanfstein B, Shlyakhto V, Lauseker M, **Hehlmann R,** Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; for the SAKK and the German CML Study Group. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib *Leukemia.* 2014 Oct;28(10):1988-92

Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, **Hehlmann R;** for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia. *J Cancer Res Clin Oncol.* 2014 Aug;140(8):1367-81

Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrmann M, Hochhaus A, Hasford J, **Hehlmann R,** Saußele S; for the German Chronic Myeloid Leukemia Study Group, and the SAKK. Older patients with chronic myeloid leukemia (≥ 65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. *Ann Hematol.* 2014 Jul;93(7):1167-76

Lauseker M, Hasford J, Pfirrmann M, **Hehlmann R;** German CML Study Group. The impact of health care settings on survival time of patients with chronic myeloid leukemia. *Blood.* 2014 Apr 17;123(16):2494-6

Hehlmann R, Müller M C, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge Ch, Kanz L, Neubauer A, Kneba M, Stegelmann Fr, Pfreundschuh M, Waller C F, Spiekermann K, Baerlocher G M, Ehninger G, Heim D, Heimpel H, Nerl Ch, Krause S W, Hossfeld D K, Kolb H-J, Hasford J, Saußele S, and Hochhaus A. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. *J Clin Oncol.* 2014 Feb 10;32(5):415-23

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, **Hehlmann R**; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für SAKK. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. *Ann Hematol.* 2014 Jan;93(1):71-80